Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.53 |
| ▸ | CCNE2 | O96020 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CDK4 | P11802 | 4/20 | 0.49 |
| ▸ | CDK1 | P06493 | 3/20 | 0.49 |
| ▸ | CCND1 | P24385 | 3/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.49 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.49 |
| ▸ | CCND2 | P30279 | 1/20 | 0.49 |
| ▸ | CCND3 | P30281 | 1/20 | 0.49 |
| ▸ | OGA | O60502 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233711 | 0.81 | CDK2 (0.60) | CDK2CCNE1CCNE2LMNAMAPT | |
| SCHEMBL12523827 | 0.81 | LMNA (0.55) | CDK2CCNE1CCNE2LMNAMAPT | |
| SCHEMBL4972075 | 0.80 | LMNA (0.53) | CDK2CCNE1CCNE2LMNAMAPT | |
| SCHEMBL4963441 | 0.80 | LMNA (0.53) | CDK2CCNE1CCNE2LMNAMAPT | |
| SCHEMBL16113800 | 0.80 | LMNA (0.57) | CDK2CCNE1CCNE2LMNAMAPT | |
| SCHEMBL31128699 | 0.79 | LMNA (0.52) | CDK2CCNE1CCNE2LMNAMAPT | |
| SCHEMBL21358854 | 0.79 | LMNA (0.52) | CDK2CCNE1CCNE2LMNAMAPT | |
| SCHEMBL18135139 | 0.79 | CDK2 (0.64) | CDK2CCNE1CCNE2LMNAMAPT | |
| SCHEMBL7992945 | 0.78 | CCNE1 (0.48) | CDK2CCNE1CCNE2LMNAMAPT | |
| SCHEMBL21359464 | 0.78 | CCNE1 (0.48) | CDK2CCNE1CCNE2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | ASCENEURON SA (CH) | 2023-08-22 | — | — | US | disclosed |
| US-20220143042-A1 | FUSED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-05-12 | — | — | US | disclosed |
| US-20210213005-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-15 | — | — | US | disclosed |
| US-20210206766-A1 | SPIRO COMPOUNDS AS GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-08 | — | — | US | disclosed |
| WO-2020039027-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143042-A1 | FUSED GLYCOSIDASE INHIBITORS | BACE1, ENGASE, GBA3 | CDK2 2649/4885CCNE1 1000/4885CCNE2 2103/4885 |
| US-20210213005-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | PREP, GAA, DNPEP | CDK2 1834/4885CCNE1 1547/4885CCNE2 2544/4885 |
| US-20210206766-A1 | SPIRO COMPOUNDS AS GLYCOSIDASE INHIBITORS | GLA, BACE1, GAA | CDK2 1327/4885CCNE1 713/4885CCNE2 755/4885 |
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | GLA, BACE1, GAA | CDK2 1327/4885CCNE1 713/4885CCNE2 755/4885 |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | BACE1, BACE2, BCHE | CDK2 678/4885CCNE1 434/4885CCNE2 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.